Related Experiment Video
Updated: Jun 14, 2026
07:23
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Genetic polymorphisms and human sensitivity to opioid analgesics.
Daisuke Nishizawa1, Masakazu Hayashida, Makoto Nagashima
1Division of Psychobiology, Tokyo Institute of Psychiatry, Tokyo, Japan.
Methods in Molecular Biology (Clifton, N.J.)
|March 26, 2010
Summary
Genetic variations influence how individuals respond to opioid pain relievers. Understanding these genetic differences can help personalize opioid dosages for better pain management.
Area of Science:
- Pharmacogenetics
- Pain Management
- Genetics
Background:
- Opioid analgesics are vital for managing moderate to severe acute and chronic pain.
- Significant inter-individual variability exists in patient responses to opioids, complicating effective pain treatment.
- Research linking human genetic variations to opioid sensitivity is limited and in its nascent stages.
Purpose of the Study:
- To explore the association between genetic variations and individual differences in opioid sensitivity.
- To provide valuable insights for the personalized dosing of opioids for adequate pain control.
- To summarize protocols for investigating genetic polymorphisms and opioid sensitivity in human subjects.
Main Methods:
- Review and summarization of methodologies for association studies.
- Focus on investigating genetic polymorphisms in candidate genes.
- Application in human volunteers and patients undergoing painful surgery.
Main Results:
- Limited studies currently exist on the relationship between human genetic variations and opioid sensitivity.
- Further research is needed to establish clear links between specific genetic variations and opioid response.
- Protocols for future studies are proposed.
Conclusions:
- Establishing the link between genetic variations and opioid sensitivity is crucial for personalized pain management.
- Individualized opioid dosing based on genetic profiles can optimize pain relief and treatment outcomes.
- Further investigation into pharmacogenetics is essential for advancing pain therapy.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...